Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
Fiche publication
Date publication
mars 2019
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
Tous les auteurs :
Phan C, Beauchet A, Burztejn AC, Severino-Freire M, Barbarot S, Girard C, Lasek A, Reguiai Z, Hadj-Rabia S, Abasq C, Brenaut E, Droitcourt C, Perrussel M, Mallet S, Phan A, Lacour JP, Khemis A, Bourrat E, Chaby G, Deborde R, Plantin P, Maruani A, Piram M, Maccari F, Fougerousse AC, Kupfer-Bessaguet I, Balguérie X, Barthelemy H, Martin L, Quiles-Tsimaratos N, Mery-Brossard L, Pallure V, Lons-Danic D, Bouilly-Auvray D, Beylot-Barry M, Puzenat E, Aubin F, Mahé E E, ,
Lien Pubmed
Résumé
Three biotherapies - etanercept, adalimumab, and ustekinumab - are licensed in childhood psoriasis. The few data available on their efficacy and tolerance are mainly derived from industry trials. However, biological drug survival impacts long-term performance in real-life settings.
Référence
J Eur Acad Dermatol Venereol. 2019 Mar 18;: